Breaking Finance News

Cantor Fitzgerald downgraded Tobira Therapeutics Inc (NASDAQ:TBRA) to Hold in a statement released earlier today.

Cantor Fitzgerald has downgraded Tobira Therapeutics Inc (NASDAQ:TBRA) to Hold in a report released on 09/21/2016.

Previously on Wednesday July 06, 2016, Cantor Fitzgerald reported on Tobira Therapeutics Inc (NASDAQ:TBRA) raised the target price from $0.00 to $27.00. At the time, this indicated a possible upside of 1.20%.

Yesterday Tobira Therapeutics Inc (NASDAQ:TBRA) traded -0.99% lower at $38.91. TBRA’s 50-day average is $8.62 and its two hundred day moving average is $8.93. The last stock price is up 338.18% relative to the two hundred day average, compared to the S&P 500 which has decreased -0.01% over the date range. Trading volume was down over the average, with 563,332 shares of TBRA changing hands under the typical 627,316

Performance Chart

Tobira Therapeutics Inc (NASDAQ:TBRA)

With a total market value of $0, Tobira Therapeutics Inc has with a one year low of $3.76 and a one year high of $41.39 .

A total of 3 equity analysts have released a report on Tobira Therapeutics Inc. One analyst rating the company a strong buy, two brokerages rating the company a buy, 0 equity analysts rating the company a hold, 0 firms rating the stock a underperform, and finally zero brokers rating the stock a sell with a average stock price target of $20.33.

Brief Synopsis On Tobira Therapeutics Inc (NASDAQ:TBRA)

Tobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *